NCT06350032 - Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

preservative-free parenteral treprostinil

Continuous infusion of either SC or IV preservative-free treprostinil. The dosing is not stipulated by the study protocol and will be done according to patient needs.

Trial Locations (5)

1090

RECRUITING

Medizinische Universität Wien, Vienna

28034

RECRUITING

Ramón y Cajal University Hospital, Madrid

75015

RECRUITING

Necker-Enfants Malades Hospital, Paris, Paris

H-1096

RECRUITING

Gottsegen National Cardiovascular Center, Budapest

Unknown

RECRUITING

Pediatric Cardiac Center, Bratislava